<DOC>
	<DOCNO>NCT01100528</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , dacarbazine , work different way stop growth tumor cell , either kill cell stop dividing . Recombinant interferon alfa-2b may interfere growth tumor cell . Giving interferon alfa-2b together dacarbazine may effective treatment primary uveal melanoma . PURPOSE : This phase II trial study well give dacarbazine together recombinant interferon alfa-2b work treat patient primary uveal melanoma genetic imbalance .</brief_summary>
	<brief_title>Dacarbazine Recombinant Interferon Alfa-2b Treating Patients With Primary Uveal Melanoma With Genetic Imbalance</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I. Assess disease-free survival ( DFS ) sequential dacarbazine interferon-alfa-2b adjuvant primary therapy patient uveal melanoma genetic imbalance . SECONDARY OBJECTIVES : I . Evaluate side effect assess safety patient population . II . Examine relationship level plasma biomarkers immune function tumor invasion clinical outcome . OUTLINE : Patients receive dacarbazine IV day 1 29 . Beginning 4 week second dose dacarbazine , patient receive recombinant interferon alfa-2b subcutaneously 3 time week 24 week absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 6 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Inclusion Patients must diagnosis , either cytologic histologic , melanoma iris , ciliary body and/or choroid Patient 's tumor must exhibit monosomy 3 and/or 8q amplification determine karyotype , CGH , PCRbased microsatellite , and/or FISH analysis ; tissue cell analysis obtain enucleation , resection , FNA Patients must undergo adequate primary therapy ; include enucleation , brachytherapy , proton beam radiotherapy , stereotactic irradiation , transscleral local resection , transretinal resection diode laser thermotherapy Patients must chest Xray hepatic ultrasound image method CT MRI eliminate distant disease Patients must performance status ( ECOG ) &lt; 2 Patients must enter within 56 day complete primary therapy WBC ≥ 3.0 x 10^9/L Neutrophils ≥ 1.5 x 10^9/L Platelets ≥ 100 x 10^9/L INR PTT &lt; 1.5 x upper limit normal Hemoglobin ≥ 10 gm/100 ml Creatinine ≤ 2 mg/dl Bilirubin ( total ) ≤ 1.5 mg/dl ALT ≤ 1.5 x upper limit normal Alkaline phosphatase ≤ 1.5 x upper limit normal AST ≤ 1.5 x upper limit normal Patients must receive systemic therapy melanoma Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , inform treat physician immediately All patient must inform investigational nature study must provide write informed consent accordance institutional federal guideline ; copy inform consent document sign patient must give patient Exclusion Patients metastasis Patients pregnant breastfeeding Patients may receive investigational agent Patients history immunodeficiency autoimmune diseases eligible ; patient require therapy corticosteroid immunosuppressive eligible ; patient require ongoing replacement therapy physiologic dose corticosteroid eligible . Patients uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement eligible Patients know positive HIV HepBAg No patient may malignancy malignant melanoma , follow exception : basal squamous cell carcinoma skin ; carcinoma insitu uterine cervix ; malignancy treat curative intent complete remission &gt; 3 year Patients organ allograft</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>